ALLMedicine™ Multiple Sclerosis Center
Research & Reviews 18,962 results
The American Journal of Gastroenterology; Millie L, Raymond C et. al.
Dec 2nd, 2021 - P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.|2021|Millie L,Raymond C,Jonathan C,Marc P,Ashwini P,|
BMJ Case Reports; Muaddi L, Osman O et. al.
Dec 2nd, 2021 - Central pontine myelinolysis (CPM) develops due to acute hypernatremia from a normal baseline serum sodium in the setting of electrolyte abnormalities induced by topiramate use. Topiramate is a commonly used medication with several indications inc...
Brain : a Journal of Neurology; Liebmann M, Korn L et. al.
Dec 2nd, 2021 - Dimethyl fumarate, an approved treatment for relapsing-remitting multiple sclerosis, exerts pleiotropic effects on immune cells as well as CNS resident cells. Here, we show that dimethyl fumarate exerts a profound alteration of the metabolic profi...
Multiple Sclerosis (Houndmills, Basingstoke, England); Thompson AJ, Carroll W et. al.
Dec 2nd, 2021 - Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent approvals of ocrelizumab for primary progressive MS and siponimod for active secondary progressive MS have opened the therapeutic door, though res...
Journal of Telemedicine and Telecare; Pagliari C, Di Tella S et. al.
Dec 2nd, 2021 - Multiple sclerosis is an inflammatory and neurodegenerative disorder of the central nervous system that can lead to severe motor disability. The aim of this study was to verify the health care effects of an integrated telerehabilitation approach i...
Guidelines 15 results
Archives of Physical Medicine and Rehabilitation; Costa SL, Pandey K et. al.
Sep 29th, 2020 - Vision Problems in Multiple Sclerosis.|2020|Costa SL,Pandey K,Hrdina J,Rondon M,Devos H,|
Neurology Kapoor R, Smith KE et. al.
Jul 18th, 2020 - There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes...
Archives of Physical Medicine and Rehabilitation; Siengsukon C, Karahan AY et. al.
May 14th, 2020 - Practical Sleep Information for People With Multiple Sclerosis.|2020|Siengsukon C,Karahan AY,Strober L,|
Multiple Sclerosis and Related Disorders; Lebrun C, Vukusic S et. al.
Jun 5th, 2019 - To establish recommendations on immunization for patients with multiple sclerosis (MS) BACKGROUND: Vaccines have been suspected in the past to trigger MS and relapses. With the extension of the immunoactive treatment arsenal, other concerns have b...
Clinical Nutrition (Edinburgh, Scotland); Burgos R, Bretón I et. al.
Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...
Drugs 339 results see all →
Clinicaltrials.gov 834 results
Nov 25th, 2021 - Chronic Venous Disease (CVD) is a widespread clinical condition widely spread in the western countries, with a prevalence ranging from 10% in adults younger than 30 years of age to nearly 80% for individuals >70 years of age. CVD clinical manifest...
Nov 25th, 2021 - This study will be a multicenter, randomized, double-blind, placebo-controlled study with a blinded Main Treatment Period (MT) and an Open Label Period (OLE) to evaluate the efficacy, safety, and tolerability of IMU-838 in adult patients with RMS....
Nov 25th, 2021 - Objective The original goals of this pilot study were to assess whether: (1) manganese-enhanced magnetic resonance imaging (MEMRI) using mangafodipir trisodium, a contrast agent that enters the intracellular compartment, can detect multiple sclero...
Nov 24th, 2021 - The DanNORMS study will include patients with active multiple sclerosis aged 18-65 years. Patients will be randomized in a 2:1 ratio to either rituximab or ocrelizumab. The study duration is 24 months, and patients can continue in an extension pha...
Nov 23rd, 2021 - Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to obtain data on lo...
News 2,812 results
Nov 30th, 2021 - The patient has probably transitioned to the secondary progressive form of multiple sclerosis (MS). Four phenotypes have been identified in MS, with relapsing-remitting MS (RRMS) representing the most common and secondary progressive MS (SPMS) the.
Nov 30th, 2021 - Higher coffee consumption was tied to slower cognitive decline and less cerebral amyloid-beta accumulation over 126 months, an Australian study showed. (Frontiers in Aging Neuroscience) Physical activity may promote synaptic and cognitive resilien...
Nov 23rd, 2021 - A deep learning model accurately detected cognitive decline from clinical notes up to 4 years before patients were diagnosed with mild cognitive impairment. (JAMA Network Open) Subjective sleep difficulties were associated with self-perceptions of...
Nov 17th, 2021 - The European Commission (EC) has approved diroximel fumarate (Vumerity, Biogen Inc) for treatment of adults with relapsing-remitting multiple sclerosis (MS). The approval follows a thumbs-up from the Committee for Medicinal Products for Human Use ...
Nov 10th, 2021 - This transcript has been edited for clarity. Hi. I'm Stephen Krieger from Mount Sinai in New York, here with an update from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress, which was not held in Vienna as...